Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results
April 26, 2022 08:30 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Announces Poster Presentation at American Association for Cancer Research:
April 12, 2022 08:30 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
March 24, 2022 16:05 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer,...
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET
March 23, 2022 08:30 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela to Participate in the 34th Annual Roth Conference
March 10, 2022 08:30 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results
March 08, 2022 08:30 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
March 07, 2022 08:30 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 07, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
February 22, 2022 08:00 ET
|
Panbela Therapeutics, Inc.
Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needsCombined pipeline extends from pre-clinical to...
Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
January 26, 2022 09:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting
January 24, 2022 09:00 ET
|
Panbela Therapeutics, Inc.
Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care...